HeyJaredShreyasi Asthana
- Indexed articles, last 90 days
- 12
- Latest publication
- Aug 19, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 6, 2026
Latest articles
Doravirine Add-On Boosts Virologic Control in HIV Infection (opens the original)
Read excerpt
Adding doravirine to existing antiretroviral therapy (ART) regimens helped achieve virologic control in people living with HIV with a recent viral rebound or prolonged low-level viremia. “This study suggests that adding doravirine to other active drugs (high GSS) can be an effective strategy for managing recent virological failures. However, this strategy is less effective with prolonged low-level viremia, but it may be considered on a case-by-case basis,” the authors wrote. The study was led by
Ivacaftor Boosts Height and Lung Function in Cystic Fibrosis (opens the original)
Read excerpt
Ivacaftor therapy was associated with accelerated linear growth and improved lung function in children and young adults with cystic fibrosis (CF) vs untreated control individuals, resulting in greater attained height and forced vital capacity (FVC) by age 20 years. These benefits were more pronounced among participants with severe CFTR variants. “In summary, this study provides strong evidence that CFTR modulators can optimize somatic and pulmonary development when initiated in childhood. As suc
Riociguat Cuts Pulmonary Vascular Resistance in Early PVD (opens the original)
Read excerpt
Riociguat significantly reduced pulmonary vascular resistance (PVR) over 24 weeks in patients with early pulmonary vascular disease (PVD) and was safe and well tolerated, a phase 2a trial showed. “The significant improvement in PVR indicates that riociguat may confer hemodynamic benefit in patients with early pulmonary vascular changes, potentially delaying disease progression,” the authors wrote. The study was led by Panagiota Xanthouli, MD, Centre for Pulmonary Hypertension, Thoraxklinik Heide
Benralizumab Cuts Mucus Burden in Severe Eosinophilic Asthma (opens the original)
Read excerpt
Treatment with benralizumab significantly reduced overall mucus burden in patients with severe eosinophilic asthma (SEA), with total mucus volume and mucus plug scores decreasing from baseline to 13 weeks. Overall, benralizumab demonstrated a favorable safety profile, with no new safety concerns or deaths noted. “These findings align with previous observations that benralizumab significantly reduced mucus burden and improved asthma control in patients with poorly controlled eosinophilic asthma,”
Pneumonia Exposes Hidden Immune Deficiencies (opens the original)
Read excerpt
Invasive pneumococcal disease (IPD) revealed undiagnosed blood cancers and monoclonal gammopathy of undetermined significance (MGUS) in a considerable proportion of adult patients, a Swedish study found. "Our findings suggest that assessment of M protein and Ig levels could be considered in adults with IPD, as an episode of IPD may unmask a previously undiagnosed B-cell malignancy or immunodeficiency," the authors wrote. The study was led by Tor Härnqvist, Department of Infectious Diseases, Inst
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.